Aromatase Expression Increases the Survival and Malignancy of Estrogen Receptor Positive Breast Cancer Cells

被引:17
|
作者
De Mukhopadhyay, Keya [1 ]
Liu, Zhao [1 ]
Bandyopadhyay, Abhik [1 ]
Kirma, Nameer B. [3 ]
Tekmal, Rajeshwar R. [2 ,4 ]
Wang, Shui [5 ]
Sun, Lu-Zhe [1 ,4 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
[5] Nanjing Med Univ, Affiliated Hosp 1, Dept Breast Surg, Nanjing, Jiangsu, Peoples R China
来源
PLOS ONE | 2015年 / 10卷 / 04期
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
ADIPOSE STROMAL CELLS; INHIBITORS; GENE; METASTASIS; INDUCTION; PROMOTER; ALPHA; MCF-7; CYP19;
D O I
10.1371/journal.pone.0121136
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In postmenopausal women, local estrogen produced by adipose stromal cells in the breast is believed to support estrogen receptor alpha (ERa) positive breast cancer cell survival and growth. This raises the question of how the ERa positive metastatic breast cancer cells survive after they enter blood and lymph circulation, where estrogen level is very low in postmenopausal women. In this study, we show that the aromatase expression increased when ERa positive breast cancer cells were cultured in suspension. Furthermore, treatment with the aromatase substrate, testosterone, inhibited suspension culture-induced apoptosis whereas an aromatase inhibitor attenuated the effect of testosterone suggesting that suspended circulating ERa positive breast cancer cells may up-regulate intracrine estrogen activity for survival. Consistent with this notion, a moderate level of ectopic aromatase expression rendered a non-tumorigenic ERa positive breast cancer cell line not only tumorigenic but also metastatic in female nude mice without exogenous estrogen supplementation. The increased malignant phenotype was confirmed to be due to aromatase expression as the growth of orthotopic tumors regressed with systemic administration of an aromatase inhibitor. Thus, our study provides experimental evidence that aromatase plays an important role in the survival of metastatic ERa breast cancer cells by suppressing anoikis.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Aromatase expression contributes to the survival and metastasis of estrogen receptor positive breast cancer cells
    Sun, L. Z.
    Mukhopadhyay, K.
    Liu, Z.
    Bandyopadhyay, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S57 - S57
  • [2] Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer
    Andrea Friesenhengst
    Tamara Pribitzer-Winner
    Heidi Miedl
    Katharina Pröstling
    Martin Schreiber
    [J]. Hormones and Cancer, 2018, 9 : 128 - 138
  • [3] Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer
    Friesenhengst, Andrea
    Pribitzer-Winner, Tamara
    Miedl, Heidi
    Proestling, Katharina
    Schreiber, Martin
    [J]. HORMONES & CANCER, 2018, 9 (02): : 128 - 138
  • [4] Differential Effects of Aromatase Inhibitors and Antiestrogens on Estrogen Receptor Expression in Breast Cancer Cells
    Smollich, Martin
    Goette, Martin
    Fischgraebe, Jeanett
    Radke, Isabel
    Kiesel, Ludwig
    Wuelfing, Pia
    [J]. ANTICANCER RESEARCH, 2009, 29 (06) : 2167 - 2171
  • [5] Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells
    Jin, Ming Li
    Kim, Young Woong
    Jin, Hong Lan
    Kang, Hoin
    Lee, Eun Kyung
    Stallcup, Michael R.
    Jeong, Kwang Won
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (11) : 2871 - 2883
  • [6] Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer
    Agrawal, Anil
    Ziolkowski, Piotr
    Grzebieniak, Zygmunt
    Jelen, Michal
    Bobinski, Piotr
    Agrawal, Siddarth
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (08) : 550 - 555
  • [7] Androgen receptor in estrogen receptor positive breast cancer: Beyond expression
    Basile, Debora
    Cinausero, Marika
    Iacono, Donatella
    Pelizzari, Giacomo
    Bonotto, Marta
    Vitale, Maria Grazia
    Gerratana, Lorenzo
    Puglisi, Fabio
    [J]. CANCER TREATMENT REVIEWS, 2017, 61 : 15 - 22
  • [8] Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
    Makhlin, Igor
    McAndrew, Nicholas P.
    Wileyto, E. Paul
    Clark, Amy S.
    Holmes, Robin
    Bottalico, Lisa N.
    Mesaros, Clementina
    Blair, Ian A.
    Jeschke, Grace R.
    Fox, Kevin R.
    Domchek, Susan M.
    Matro, Jennifer M.
    Bradbury, Angela R.
    Feldman, Michael D.
    Hexner, Elizabeth O.
    Bromberg, Jacqueline F.
    DeMichele, Angela
    [J]. NPJ BREAST CANCER, 2022, 8 (01)
  • [9] Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
    Igor Makhlin
    Nicholas P. McAndrew
    E. Paul Wileyto
    Amy S. Clark
    Robin Holmes
    Lisa N. Bottalico
    Clementina Mesaros
    Ian A. Blair
    Grace R. Jeschke
    Kevin R. Fox
    Susan M. Domchek
    Jennifer M. Matro
    Angela R. Bradbury
    Michael D. Feldman
    Elizabeth O. Hexner
    Jacqueline F. Bromberg
    Angela DeMichele
    [J]. npj Breast Cancer, 8
  • [10] Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
    Pin Gao
    Xiang Wang
    Ying Jin
    Wenquan Hu
    Yajun Duan
    Aiping Shi
    Ye Du
    Dong Song
    Ming Yang
    Sijie Li
    Bing Han
    Gang Zhao
    Hongquan Zhang
    Zhimin Fan
    Qing Robert Miao
    [J]. Breast Cancer Research, 20